Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Study Details
Study Description
Brief Summary
This is a prospective, single-arm, multicenter Phase II study of patients with advanced HR+/HER2- breast cancer who are untreated or have failed previous first-line endocrine therapy。The primary objective of this study was to explore the efficacy and safety of the PD-L1 inhibitor adebrelimab in combination with the CDK4/6 inhibitor Dalpiciclib and standard endocrine therapy in advanced HR+/ HER2-breast cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: treatment group Adebrelimab: 1200mg intravenously ,Q3W dalpiciclib : 150mg once a day for 3 weeks, stop for 1 week, Q4W Endocrine recommended drugs untreated: aromatase inhibitors (letrozole/anastrozole/exemestane), given orally once daily at a specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, exemestane 25mg/ day); first-line endocrine therapy failed: fluvestrant was given once every 28 days, 500mg intramuscular injection, and then 500mg intramuscular injection 2 weeks after the first administration; |
Drug: Adebrelimab
adebrelimab:1200mg intravenously, Q3W.
Other Names:
Drug: dalpiciclib
dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Progression-free survival(PFS) [Up to 3 years]
PFS is defined as the time from enrollment to the first imaging disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator.
Secondary Outcome Measures
- Objective response rate (ORR) [Up to 3 years]
ORR is defined as the proportion of patients with complete response(CR) and partial response(PR) assessed by the investigator in accordance with the RECIST 1.1 criteria.
- Overall survival (OS) [Up to 5 years]
OS is defined as the time between enrollment and the patient's death due to any OS is defined as the time between enrollment and the patient's death due to any cause
- Safety and Tolerability [Up to 3 years]
Safety includes the adverse event profile of sintilimab and bevacizumab according to the Common Terminology Criteria for Adverse Events version 5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Premenopausal/perimenopausal or postmenopausal women aged ≥18 years and ≤75 years;
-
Histologically confirmed HR+/HER2- invasive breast cancer (specific definition: ER
10% tumor cell positive is defined as ER positive, PR >10% tumor cell positive is defined as PR positive, ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 ++ but negative by FISH test, no amplification, defined as HER2 negative);
-
Locally advanced breast cancer (radical local treatment is not possible) or recurrent metastatic breast cancer;
-
Did not receive any systemic anti-cancer therapy at the stage of recurrence and metastasis or failed to receive first-line endocrine therapy at the advanced stage;
-
Have at least one measurable lesion according to RECIST version 1.1
-
Adequate hematology and organ function, including:
hemoglobin > 9 g/dL without blood transfusion or erythropoietin in the past 14 days.
ANC ≥ 1.5×109/L without using granulocyte colony stimulating factor in the past 14 days.
PLT ≥ 75×109/L without blood transfusion in the past 14 days. TBIL ≤ 1.5 ×ULN (Gilbert syndrome allows ≤ 3 × ULN). ALT and AST ≤ 3 × ULN (if there is liver metastasis, ALT and AST ≤ 5 × ULN). Serum Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
-
ECOG score 0 or 1, and life expectancy ≥3 months;
-
Fertile female subjects are required to use a medically approved contraceptive during the study treatment period and for at least 3 months after the last use of the study drug;
-
Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.
Exclusion Criteria:
-
Previous use of CDK4/6 inhibitors or PD1/PD-L1 monoclonal antibody
-
Uncontrolled central nervous system metastasis (meaning symptoms or the use of glucocorticoids or mannitol to control symptoms);
-
A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;
-
Radiotherapy, chemotherapy, surgery, or other targeted and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks prior to first administration of the study drug;
-
Pregnant or lactating patients;
-
Malignant tumors within the past three years (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ);
-
Significant comorbidities, including mental illnesses that the investigator believes will adversely affect the patient's participation in the study;
-
Those who have received anti-tumor vaccine or have received live vaccine within 4 weeks before the first administration of the investigational drug;
-
Patients with known HBV or HCV infection active phase or HBV DNA≥500, or chronic phase with abnormal liver function;
-
History of active autoimmune disease (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
-
A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; History of interstitial lung disease (except radiation pneumonia without hormone therapy) and non-infectious pneumonia;
-
Patients with active infection or who had been treated with systemic immune stimulating factors within 4 weeks prior to enrollment;
-
Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;
-
Previous thyroid dysfunction;
-
The investigator did not consider the patient suitable for participation in any other conditions of the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology | Wuhan | Hubei | China | 430000 |
Sponsors and Collaborators
- Tongji Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TJ-IRB20231105